Home / Stock ratings / BIO
Stock rating · Laboratory Analytical Instruments
Bio-Rad Laboratories, Inc. Class A (BIO) Stock Rating & Analysis
As of October 6, 2026, MELANY rates Bio-Rad Laboratories, Inc. Class A 60 out of 100 (Hold). Its highest factor score is catalyst setup at 88, and its lowest is valuation at 30.
MELANY ratingRated 2026-10-06BIO · composite score
About Bio-Rad Laboratories, Inc. Class A
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), it sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it makes instruments and reagents used in research, biopharmaceutical production, and food testing, and holds a leadership position in dPCR technology.
Rating as of 2026-10-06 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why BIO scores 60/100
BIO's 8 factor scores run from 30 to 88, and 4 of them sit above its composite of 60. Here is how BIO breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 52%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Avg EPS beat +13%
- Earnings in 23 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 23 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How BIO compares
As of October 13, 2026, Bio-Rad Laboratories, Inc. Class A ranks 3rd of the 4 companies with a MELANY rating page in its SEC industry group (Laboratory Analytical Instruments), where the average score is 63.
Key risks for BIO
- Trading near 52-week high, limited upside without new positive catalyst
Sector and theme context
Bio-Rad Laboratories, Inc. Class A sits in the Healthcare sector theme, which MELANY currently rates 41/100 for strength. Theme strength feeds BIO's momentum and catalyst factors above.
Tracking BIO
Bio-Rad Laboratories, Inc. Class A rates Hold right now, so MELANY is not flagging a fresh entry. Add BIO to a watchlist in the app to follow its rating; an alert the moment it changes is part of Pro, free for 30 days.
How MELANY rates BIO
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Bio-Rad Laboratories, Inc. Class A's 60/100 reflects mature factor weighting for its profile.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about BIO
Is Bio-Rad Laboratories, Inc. Class A (BIO) a buy?
As of 2026-10-06, MELANY rated Bio-Rad Laboratories, Inc. Class A Hold with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Bio-Rad Laboratories, Inc. Class A's MELANY score?
Bio-Rad Laboratories, Inc. Class A (BIO) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the BIO stock rating calculated?
MELANY scores BIO from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Bio-Rad Laboratories, Inc. Class A stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Bio-Rad Laboratories, Inc. Class A (BIO) Hold with a composite of 60/100 as of 2026-10-06. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the BIO stock price forecast?
MELANY does not publish price targets or forecasts for BIO. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Bio-Rad Laboratories, Inc. Class A, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is BIO stock overvalued or undervalued?
MELANY's valuation factor currently reads 30/100 for Bio-Rad Laboratories, Inc. Class A, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives BIO's read.
What price should I buy BIO at?
MELANY is not flagging a fresh entry for BIO at its current Hold rating, so there is no entry zone to publish right now. Add BIO to a watchlist in the app to follow it; an alert the moment the rating changes is part of Pro, free for 30 days.
What are the risks of buying BIO stock?
The top risks MELANY currently flags for Bio-Rad Laboratories, Inc. Class A: Trading near 52-week high, limited upside without new positive catalyst. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Bio-Rad Laboratories, Inc. Class A a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 54/100 for Bio-Rad Laboratories, Inc. Class A, and earnings track record, at 80/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will BIO stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 74/100 for BIO right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this BIO rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-06. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores BIO continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, BIO included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.